Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 0284

Drug Profile

AZD 0284

Alternative Names: AZD0284

Latest Information Update: 21 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Antipsoriatics; Small molecules
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Plaque psoriasis; Respiratory tract disorders

Most Recent Events

  • 24 Oct 2019 AstraZeneca completes a phase-I clinical trial in Plaque psoriasis (In volunteers) in United Kingdom (PO, Liquid) (NCT02976831)
  • 24 Jun 2018 Biomarkers information updated
  • 11 Apr 2018 AstraZeneca suspends a phase I trial in Plaque psoriasis in Denmark due to evaluation of preclinical data (NCT03310320)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top